<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d52a823a-35bd-4c6a-a016-4b4f21a43d7d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use JESDUVROQ safely and effectively. See full prescribing information for JESDUVROQ.<br/>
      <br/>JESDUVROQ (daprodustat) tablets, for oral use<br/>Initial U.S. Approval: 2023</title>
   <effectiveTime value="20230830"/>
   <setId root="d82aa06e-5a33-4844-99b7-4701313455a4"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="167380711" root="1.3.6.1.4.1.519.1"/>
            <name>GlaxoSmithKline LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f3933f3f-3d3c-4f5c-ae55-bf525e48f7aa"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230830"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0173-0897" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Jesduvroq</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>daprodustat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPRODUSTAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPRODUSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0173-0897-13" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230201"/>
                                    <high value="20270131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0173-0897-56" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230201"/>
                                          <high value="20230202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216951" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20230201"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230201"/>
                              <high value="20270131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48324" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAY" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GS;KF</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0173-0903" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Jesduvroq</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>daprodustat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPRODUSTAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPRODUSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0173-0903-13" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230201"/>
                                    <high value="20270430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0173-0903-56" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230201"/>
                                          <high value="20230202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216951" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20230201"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230201"/>
                              <high value="20270430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GS;V7</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0173-0906" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Jesduvroq</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>daprodustat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="4"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPRODUSTAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPRODUSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0173-0906-13" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230201"/>
                                    <high value="20270430"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0173-0906-56" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230201"/>
                                          <high value="20230202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216951" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20230201"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230201"/>
                              <high value="20270430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GS;13</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0173-0911" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Jesduvroq</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>daprodustat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="6"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPRODUSTAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPRODUSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0173-0911-13" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230201"/>
                                    <high value="20261130"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0173-0911-56" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230201"/>
                                          <high value="20230202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216951" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20230201"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230201"/>
                              <high value="20261130"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GS;IM</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0173-0914" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Jesduvroq</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>daprodustat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="8"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DAPRODUSTAT</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JVR38ZM64B" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DAPRODUSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0173-0914-13" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20230201"/>
                                    <high value="20261130"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0173-0914-56" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20230201"/>
                                          <high value="20230202"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216951" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <effectiveTime>
                              <low value="20230201"/>
                           </effectiveTime>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20230201"/>
                              <high value="20261130"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">GS;5E</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_d41c4bf4-f511-48f2-aa47-e6ea7b56930a">
               <id root="6dd6c2bc-7c81-46ae-976b-a4630435029f"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
               <title>WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">JESDUVROQ increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">5.1</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">5.1</linkHtml>)]</content>.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">No trial has identified a hemoglobin target level, dose of JESDUVROQ, or dosing strategy that does not increase these risks <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>)].</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood cell transfusions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>
                              <content styleCode="bold">JESDUVROQ increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE). (<linkHtml href="#ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption></caption>
                              <content styleCode="bold">Targeting a hemoglobin level greater than 11g/dL is expected to further increase the risk of death and arterial venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels. (<linkHtml href="#ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <caption></caption>
                              <content styleCode="bold">No trial has identified a hemoglobin target level, dose of JESDUVROQ, or dosing strategy that does not increase these risks. (<linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>)</content>
                           </item>
                           <item>
                              <caption></caption>
                              <content styleCode="bold">Use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood cell transfusions. (<linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_36c45c1d-3588-47f7-8dbe-323e090a2da3">
               <id root="99860c26-cf33-4feb-aa2f-b1c5848aa359"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <paragraph>JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being.</paragraph>
                  <paragraph>JESDUVROQ is not indicated for use:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.</item>
                     <item>
                        <caption></caption>For treatment of anemia of chronic kidney disease in patients who are not on dialysis.</item>
                  </list>
               </text>
               <effectiveTime value="20230201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>JESDUVROQ is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least four months. (<linkHtml href="#ID_36c45c1d-3588-47f7-8dbe-323e090a2da3">1</linkHtml>)</paragraph>
                        <paragraph>Limitations of Use</paragraph>
                        <paragraph>Not shown to improve quality of life, fatigue, or patient well-being.</paragraph>
                        <paragraph>Not indicated for use:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>As a substitute for transfusion in patients requiring immediate correction of anemia.</item>
                           <item>
                              <caption></caption>In patients not on dialysis.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_437a7705-47b3-4466-8e27-36ac4351a56e">
               <id root="8439c400-6de4-428d-92d8-01669721b12b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20230830"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Administer orally once daily, with or without food. (<linkHtml href="#ID_04497f16-2ccc-4a1d-8f3d-2e6d463860fc">2.2</linkHtml>, <linkHtml href="#ID_d4b5fdcc-0ea7-491b-8083-0650bfca4924">2.3</linkHtml>)</item>
                           <item>
                              <caption></caption>See Full Prescribing Information for starting dosage based on hemoglobin level, liver function and concomitant medications, and for dose titration and monitoring recommendations. (<linkHtml href="#ID_d4b5fdcc-0ea7-491b-8083-0650bfca4924">2.3</linkHtml>, <linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>, <linkHtml href="#ID_2fd12162-be3a-480a-8388-6d7a4642f027">2.5</linkHtml>, <linkHtml href="#ID_fbe0a52f-bffd-4553-9983-3e9ccdd7db41">2.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0015a512-c3b9-4d87-bc44-3876cc58d3cc">
                     <id root="57d5a2da-31e1-4316-8d6d-31cad302493a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Pre-Treatment and On-Treatment Evaluations of Anemia, Iron Stores, and Liver Tests </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Evaluation of Anemia and Iron Stores</content>
                        </paragraph>
                        <paragraph>Correct and exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) before initiating JESDUVROQ. Evaluate the iron status in all patients before and during treatment with JESDUVROQ. Administer supplemental iron therapy when serum ferritin is less than 100 ng/ml or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of therapy.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Liver Testing</content>
                        </paragraph>
                        <paragraph>Assess serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total bilirubin prior to initiation of JESDUVROQ. Repeat the liver tests if the patient develops signs or symptoms that could be consistent with liver disease during treatment with JESDUVROQ.</paragraph>
                     </text>
                     <effectiveTime value="20230713"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_04497f16-2ccc-4a1d-8f3d-2e6d463860fc">
                     <id root="7d07c656-69f0-47e8-b732-c5c3f038f2ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Important Dosing Information </title>
                     <text>
                        <paragraph>Individualize dosing and use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood cell transfusions. Do not target a hemoglobin higher than 11 g/dL.</paragraph>
                        <paragraph>JESDUVROQ can be taken with or without food, and without regard to concomitant administration of iron or phosphate binders <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>JESDUVROQ should be swallowed whole. Tablets should not be cut, crushed, or chewed.</paragraph>
                        <paragraph>JESDUVROQ can be administered without regard to the timing or type of dialysis <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>If a dose of JESDUVROQ is missed, it should be taken as soon as possible, unless it is the same day as the next dose. In this case, the missed dose should be skipped, and the next dose taken at the usual time. Double-doses should not be taken to make-up for a missed dose.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d4b5fdcc-0ea7-491b-8083-0650bfca4924">
                     <id root="35e9cfba-76cb-44d5-8858-18e856b79f82"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Starting Dose of JESDUVROQ </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults with Anemia Due to Chronic Kidney Disease Receiving Dialysis for at Least 4 Months</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adults Not Being Treated with an ESA:</content> For adults not being treated with an ESA, the starting dose of JESDUVROQ is based on the hemoglobin level (see<linkHtml href="#_RefTable1">Table 1</linkHtml>). Dose modifications are needed for patients receiving concomitant treatment with a moderate CYP2C8 inhibitor or moderate hepatic impairment <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_2fd12162-be3a-480a-8388-6d7a4642f027">2.5</linkHtml>, <linkHtml href="#ID_fbe0a52f-bffd-4553-9983-3e9ccdd7db41">2.6</linkHtml>), Drug Interactions (<linkHtml href="#ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">7.1</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_743fd794-9388-4343-8f8c-a2736186ee2b">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                        <table ID="_RefTable1" width="100%">
                           <caption>Table 1: Starting Dose of JESDUVROQ for Adults on Dialysis not Receiving an Erythropoiesis-Stimulating Agent</caption>
                           <col width="49%"/>
                           <col width="51%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Pre-Treatment Hemoglobin Level (g/dL)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Starting Dose of JESDUVROQ</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(Once Daily Dosing)<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>&lt;9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>4mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>9 to 10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>2mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>&gt;10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>1mg</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <list listType="unordered">
                           <item>
                              <caption></caption>
                              <sup>a </sup>See dosing modifications in Section 2.5 if the patient has moderate hepatic impairment and Section 2.6 if the patient is on a moderate CYP2C8 inhibitor.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Adults Being Switched from an ESA:</content> For adults being switched from an ESA to JESDUVROQ, the starting dose of JESDUVROQ is based on the dose regimen of the ESA at the time of substitution (see <linkHtml href="#_RefTable2">Table 2</linkHtml>). Dose modifications are needed for patients receiving concomitant treatment with a moderate CYP2C8 inhibitor or moderate hepatic impairment<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#ID_2fd12162-be3a-480a-8388-6d7a4642f027">2.5</linkHtml>, <linkHtml href="#ID_fbe0a52f-bffd-4553-9983-3e9ccdd7db41">2.6</linkHtml>), Drug Interactions (<linkHtml href="#ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">7.1</linkHtml>), Use in Specific Populations (<linkHtml href="#ID_743fd794-9388-4343-8f8c-a2736186ee2b">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                        <table ID="_RefTable2" width="100%">
                           <caption>Table 2: Starting Dose of JESDUVROQ for Adults on Dialysis Switching from an Erythropoiesis-Stimulating Agent</caption>
                           <col width="24%"/>
                           <col width="27%"/>
                           <col width="22%"/>
                           <col width="27%"/>
                           <tbody>
                              <tr>
                                 <td align="center" colspan="3" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Current Dose of ESA</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of JESDUVROQ<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Epoetin Alfa<sup>b</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Intravenous</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(units/week)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Darbepoetin Alfa</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Subcutaneous</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">/Intravenous</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg/4 weeks)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Methoxy PEG-Epoetin Beta</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Subcutaneous</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">/Intravenous</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(mcg/month)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Once Daily</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosing</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Less than or equal to 2,000</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>20 to 30</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>30 to 40</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than 2,000 to less than 10,000</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than</paragraph>
                                    <paragraph>30 to 150</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than</paragraph>
                                    <paragraph>40 to 180</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than or equal to 10,000 to less than 20,000</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than</paragraph>
                                    <paragraph>150 to 300</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Greater than</paragraph>
                                    <paragraph>180 to 360</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>8 mg</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Greater than or equal to 20,000</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Greater than 300</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Greater than 360</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>12 mg</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>ESA=Erythropoiesis stimulating agent.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>
                              <sup>a</sup> See dosing modifications in Section 2.5 if the patient has moderate hepatic impairment and Section 2.6 if the patient is on a moderate CYP2C8 inhibitor.</item>
                           <item>
                              <caption></caption>
                              <sup>b</sup> For patients on subcutaneous epoetin alfa, convert the epoetin alfa subcutaneous dose to intravenous dose equivalent by multiplying the subcutaneous dose received per week by 1.42 to obtain the weekly intravenous dose.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b12fd006-4c44-4ed4-8f30-0193b1896562">
                     <id root="328dfa32-27ab-47c9-b9ab-a7a8b932028a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Monitoring Response to Therapy and Dose Adjustment </title>
                     <text>
                        <paragraph>Following initiation of therapy and after each dose adjustment, monitor hemoglobin every 2weeks for the first month and then every 4 weeks thereafter.</paragraph>
                        <paragraph>When adjusting doses of JESDUVROQ, consider hemoglobin rate of rise, rate of decline and hemoglobin variability. Do not increase the dose of JESDUVROQ more frequently than once every 4 weeks.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption></caption>If the dose of JESDUVROQ needs to be adjusted, increase or decrease by one dose level at a time (see <linkHtml href="#_RefTable3">Table 3</linkHtml>).</item>
                           <item>
                              <caption></caption>Decrease the dose of JESDUVROQ if hemoglobin increases rapidly (e.g., greater than 1g/dL over 2 weeks or greater than 2g/dL over 4 weeks) or if the hemoglobin exceeds 11g/dL.</item>
                           <item>
                              <caption></caption>If hemoglobin exceeds 12g/dL<content styleCode="bold">,</content> interrupt treatment with JESDUVROQ. When the hemoglobin is within the target range, treatment may be restarted at one dose level lower (see <linkHtml href="#_RefTable3">Table 3</linkHtml>).</item>
                           <item>
                              <caption></caption>Treatment with JESDUVROQ should not be continued beyond 24weeks of therapy if a clinically meaningful increase in hemoglobin level is not achieved. Alternative explanations for an inadequate response should be sought and treated before re-starting therapy.</item>
                        </list>
                        <table ID="_RefTable3" cellpadding="1.4pt" width="100%">
                           <caption>Table 3: Dose Levels of JESDUVROQ</caption>
                           <col width="30%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="9%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Daily dose of JESDUVROQ</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>1mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>2mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>4mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>6mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>8mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>12mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>16 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>24 mg<sup>a</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup> 24 mg is the maximum recommended once daily dose.</paragraph>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2fd12162-be3a-480a-8388-6d7a4642f027">
                     <id root="c4348891-6224-473a-8592-5968ff0f7590"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modification for Hepatic Impairment </title>
                     <text>
                        <paragraph>Reduce the starting dose of JESDUVROQ by half (see <linkHtml href="#_RefTable1">Table 1</linkHtml> and <linkHtml href="#_RefTable2">Table 2</linkHtml>) in patients with moderate hepatic impairment (Child-Pugh Class B) except in patients whose starting dose is already 1 mg.</paragraph>
                        <paragraph>Use of JESDUVROQ in patients with severe hepatic impairment (Child-Pugh ClassC) is not recommended <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_743fd794-9388-4343-8f8c-a2736186ee2b">8.6</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fbe0a52f-bffd-4553-9983-3e9ccdd7db41">
                     <id root="3c566876-b57b-4254-a464-fe2d21f3c158"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modification for Concomitant Treatment with Moderate CYP2C8 Inhibitors </title>
                     <text>
                        <paragraph>Reduce the starting dose of JESDUVROQ by half (see <linkHtml href="#_RefTable1">Table 1</linkHtml> and <linkHtml href="#_RefTable2">Table 2</linkHtml>) in patients who are on clopidogrel or a moderate CYP2C8 inhibitor except in patients whose starting dose is already 1mg <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">7.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>Monitor hemoglobin and adjust the dose of JESDUVROQ when initiating or stopping therapy with clopidogrel or a moderate CYP2C8 inhibitor during treatment with JESDUVROQ.</paragraph>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c585ba97-f562-4cae-a5a4-d945aa5dde3a">
               <id root="f9085348-e041-4d1a-b702-378c5a207c10"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>1 mg, gray, biconvex, round film-coated tablets debossed with GS KF on one face.</item>
                     <item>
                        <caption></caption>2 mg, yellow, biconvex, round film-coated tablets debossed with GS V7 on one face.</item>
                     <item>
                        <caption></caption>4 mg, white, biconvex, round film-coated tablets debossed with GS 13 on one face.</item>
                     <item>
                        <caption></caption>6 mg, pink, biconvex, round film-coated tablets debossed with GS IM on one face.</item>
                     <item>
                        <caption></caption>8 mg, orange, biconvex, round film-coated tablets debossed with GS 5E on one face.</item>
                  </list>
               </text>
               <effectiveTime value="20230201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 1 mg, 2 mg, 4 mg, 6 mg, and 8 mg. (<linkHtml href="#ID_c585ba97-f562-4cae-a5a4-d945aa5dde3a">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_29ab096f-bf1d-4430-874d-6615e461b6fe">
               <id root="1d033aa4-184c-45a0-9b9a-3dd482daa5ee"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>JESDUVROQ is contraindicated in patients:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>Receiving a strong CYP2C8 inhibitor such as gemfibrozil <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">7.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>With uncontrolled hypertension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_dc714e86-7a41-4251-9423-7424fdeff516">5.3</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20230201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Strong cytochrome P450 2C8 (CYP2C8) inhibitors such as gemfibrozil. (<linkHtml href="#ID_29ab096f-bf1d-4430-874d-6615e461b6fe">4</linkHtml>)</item>
                           <item>
                              <caption></caption>Uncontrolled hypertension. (<linkHtml href="#ID_29ab096f-bf1d-4430-874d-6615e461b6fe">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_62fbcef0-e705-46e7-a79f-a874c439da0e">
               <id root="80e14a62-1c17-47a8-83a8-494fce49279d"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20230830"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Risk of Hospitalization for Heart Failure: Increased in patients with a history of heart failure. (<linkHtml href="#ID_7199c810-353e-44c5-9b7a-ae466d13183f">5.2</linkHtml>)</item>
                           <item>
                              <caption></caption>Hypertension: Worsening hypertension, including hypertensive crisis may occur. Monitor blood pressure. Adjust anti-hypertensive therapy as needed. (<linkHtml href="#ID_dc714e86-7a41-4251-9423-7424fdeff516">5.3</linkHtml>)</item>
                           <item>
                              <caption></caption>Gastrointestinal Erosion: Gastric or esophageal erosions and gastrointestinal bleeding have been reported. (<linkHtml href="#ID_8554eea2-5f45-416c-a3de-fa31306d0ec5">5.4</linkHtml>)</item>
                           <item>
                              <caption></caption>Not indicated for treatment of anemia of CKD in patients who are not dialysis-dependent (<linkHtml href="#ID_c119e973-089d-4f5d-a4b3-84dd973b8ca9">5.5</linkHtml>)</item>
                           <item>
                              <caption></caption>Malignancy: May have unfavorable effects on cancer growth. Not recommended if active malignancy. (<linkHtml href="#ID_0f10af61-ae81-467d-a4dc-5710f30c286d">5.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">
                     <id root="7ef9b522-2774-4797-8dd6-65f1f2240f1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Increased Risk of Death, Myocardial Infarction, Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access </title>
                     <text>
                        <paragraph>JESDUVROQ increases the risk of arterial and venous thrombotic events, that may be fatal, including myocardial infarction, stroke, venous thromboembolism and vascular access thrombosis <content styleCode="italics">[see Boxed Warning, Adverse Reactions (<linkHtml href="#ID_c17d0a6c-dbfc-448c-aa36-d8e07562f672">6.1</linkHtml>)]</content>. Patients with cardiovascular or cerebrovascular disease are at increased risk of these events. Avoid use in patients with a history of myocardial infarction, cerebrovascular event, or acute coronary syndrome within the 3months prior to starting JESDUVROQ.</paragraph>
                        <paragraph>A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to these risks. Targeting a hemoglobin level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with ESAs, which also increase erythropoietin levels.</paragraph>
                        <paragraph>No trial has identified a hemoglobin target level, dose of JESDUVROQ, or dosing strategy that does not increase these risks. Use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood transfusions. Adherence to dosing and hemoglobin monitoring recommendations is important to avoid excessive erythropoiesis <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>Advise patients to seek immediate medical attention if they develop signs or symptoms of myocardial infarction, stroke, venous thromboembolism, or thrombosis of vascular access. Evaluate and manage promptly if these occur.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7199c810-353e-44c5-9b7a-ae466d13183f">
                     <id root="6ebf17c0-2105-414b-b8cb-295b00c3f4cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Risk of Hospitalization for Heart Failure </title>
                     <text>
                        <paragraph>In the ASCEND-D trial, hospitalization for heart failure was observed in 7.5% (3.3 per 100 Person Years [PY]) of patients on dialysis receiving JESDUVROQ and 6.8% (3.0 per 100 PY) of patients receiving recombinant human erythropoietin (rhEPO). Patients with a pre-existing history of heart failure were at increased risk of hospitalization for heart failure with JESDUVROQ (14.5%; 6.8 per 100 PY) compared to rhEPO (11.3%; 5.1 per 100 PY).</paragraph>
                        <paragraph>Consider the patients history of heart failure when deciding whether to prescribe JESDUVROQ. Advise patients of the symptoms and signs of heart failure and to immediately report any worsening to their healthcare provider.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dc714e86-7a41-4251-9423-7424fdeff516">
                     <id root="4da82f63-747d-43ae-802c-80e76d2a1af2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypertension </title>
                     <text>
                        <paragraph>JESDUVROQ is contraindicated in patients with uncontrolled hypertension. In the ASCEND-D trial, worsening of hypertension occurred in 24% (12 per 100 PY) of patients receiving JESDUVROQ and 24% (12 per 100 PY) of patients receiving rhEPO <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_c17d0a6c-dbfc-448c-aa36-d8e07562f672">6.1</linkHtml>)]</content>. Serious worsening of hypertension occurred in 3.1% of patients receiving JESDUVROQ and 3.1% of patients receiving rhEPO. Cases of hypertensive crisis including hypertensive encephalopathy and seizures have also been reported in patients receiving JESDUVROQ. Periodically monitor blood pressure and adjust or initiate anti-hypertensive therapy as needed.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8554eea2-5f45-416c-a3de-fa31306d0ec5">
                     <id root="05f4929f-3365-4992-9acc-1d5b437bb58e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Gastrointestinal Erosion </title>
                     <text>
                        <paragraph>In the ASCEND-D trial, gastric or esophageal erosions occurred in 5.7% (2.5 per 100 PY) of patients receiving JESDUVROQ and 6.6% (2.9 per 100 PY) of rhEPO-treated patients. Serious erosions, including gastrointestinal bleeding and the need for red blood cell transfusions, were reported in 3.6% and 3.1% of those receiving JESDUVROQ and rhEPO, respectively. Consider this risk particularly in patients at increased risk for gastrointestinal erosions, such as those with a history of gastrointestinal erosion, peptic ulcer disease, use of concomitant medications that increase the risk of gastrointestinal erosion, and current tobacco smokers and alcohol drinkers.</paragraph>
                        <paragraph>Advise patients of the symptoms and signs of gastric and esophageal erosions and of gastrointestinal bleeding and to seek prompt medical care if these occur.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c119e973-089d-4f5d-a4b3-84dd973b8ca9">
                     <id root="fb217331-8b3d-45a4-a3a7-8a47197c2c09"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Serious Adverse Events in Patients with Anemia Due to Chronic Kidney Disease and Not on Dialysis </title>
                     <text>
                        <paragraph>The safety of JESDUVROQ has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting <content styleCode="italics">[see Indications and Usage (<linkHtml href="#ID_36c45c1d-3588-47f7-8dbe-323e090a2da3">1</linkHtml>)]</content>.</paragraph>
                        <paragraph>In a large cardiovascular outcomes trial in adults with anemia of CKD who were not on dialysis (ASCEND-ND), an increased risk of cardiovascular mortality, stroke, thromboembolism, serious acute kidney injury, hospitalization for heart failure, and serious gastrointestinal erosions was observed in patients treated with JESDUVROQ compared to rhEPO.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0f10af61-ae81-467d-a4dc-5710f30c286d">
                     <id root="ddeb9822-433b-48e7-90f0-7ded47ffc700"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Malignancy </title>
                     <text>
                        <paragraph>Because increased hypoxia inducible factor (HIF)-1 levels may be associated with unfavorable effects on cancer growth, JESDUVROQ has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 4.4% (1.9 per 100 PY) of patients treated with JESDUVROQ and 5.2% (2.3 per 100 PY) of patients treated with rhEPO. No evidence of increased carcinogenicity was observed in animal studies <content styleCode="italics">[see Nonclinical Toxicology (<linkHtml href="#ID_4634c38a-14c2-483b-b9ba-698c2e76e517">13.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9790bfc8-9756-4a5a-9cb3-d0f466f16b71">
               <id root="98ddbb6c-2aec-4eb7-a89b-d5706093cf5a"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>Increased Risk of Death, Myocardial Infarction, Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (<linkHtml href="#ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Risk of Hospitalization for Heart Failure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7199c810-353e-44c5-9b7a-ae466d13183f">5.2</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Hypertension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_dc714e86-7a41-4251-9423-7424fdeff516">5.3</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Gastrointestinal Erosion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_8554eea2-5f45-416c-a3de-fa31306d0ec5">5.4</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20230830"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence 10%) are hypertension, thrombotic vascular events, and abdominal pain. (<linkHtml href="#ID_c17d0a6c-dbfc-448c-aa36-d8e07562f672">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c17d0a6c-dbfc-448c-aa36-d8e07562f672">
                     <id root="15025d23-0237-48d9-85f8-528b7250d8c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of JESDUVROQ was evaluated in adults with dialysis-dependent chronic kidney disease with anemia in the ASCEND-D trial based on an on-study analysis (on and off treatment) <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_192725f0-0ca3-4c67-904c-645840982fc6">14.1</linkHtml>)]</content>. Patients were randomized to JESDUVROQ or rhEPO (epoetin alfa for patients on hemodialysis; darbepoetin alfa for patients on peritoneal dialysis). Of the 2,964 patients randomized in the trial, 1,487 were randomized to JESDUVROQ, 1,316 (88.5%) of whom were on hemodialysis and 171 (11.5%) of whom were on peritoneal dialysis.</paragraph>
                        <paragraph>The median extent of exposure to JESDUVROQ and rhEPO was similar. In the JESDUVROQ treatment arm, 65% of the participants were exposed to at least 18 months of JESDUVROQ and 29% of participants received JESDUVROQ for at least 2.5years.</paragraph>
                        <paragraph>JESDUVROQ was non-inferior to rhEPO on the time to first occurrence of major adverse cardiovascular events (MACE) in adults with anemia due to CKD who were on dialysis <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_192725f0-0ca3-4c67-904c-645840982fc6">14.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Permanent treatment discontinuation due to an adverse reaction was reported in 19% of patients treated with JESDUVROQ and 18% of patients treated with rhEPO. No specific adverse reaction resulted in permanent treatment discontinuation in &gt;1% of patients treated with JESDUVROQ.</paragraph>
                        <paragraph>The most common adverse reactions (10% of JESDUVROQ-treated patients) were hypertension, thrombotic vascular events, and abdominal pain.</paragraph>
                        <paragraph>
                           <linkHtml href="#_RefTable4">Table 4</linkHtml> lists the most common adverse reactions (reported in 5% of patients treated with JESDUVROQ).</paragraph>
                        <table ID="_RefTable4" width="100%">
                           <caption>Table 4: Adverse Reactions Reported in 5% of Patients Treated with JESDUVROQ in the ASCEND-D Trial</caption>
                           <col width="53%"/>
                           <col width="25%"/>
                           <col width="22%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JESDUVROQ</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,482)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">rhEPO</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,474)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hypertension</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>24</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>24</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abdominal pain<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Hypersensitivity<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>rhEPO=Recombinant human erythropoietin.</paragraph>
                        <paragraph>
                           <sup>a</sup> Includes unspecified abdominal pain, upper abdominal pain, abdominal discomfort.</paragraph>
                        <paragraph>
                           <sup>b</sup> Includes rash, urticaria and dermatitis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Thrombotic Vascular Events</content>
                        </paragraph>
                        <paragraph>Adjudicated thrombotic vascular events (fatal and non-fatal) were observed in 9.8 per 100 PY of patients receiving JESDUVROQ and in 11.7 per 100 PY of patients receiving rhEPO (see <linkHtml href="#_RefTable5">Table 5</linkHtml>).</paragraph>
                        <table ID="_RefTable5" width="100%">
                           <caption>Table 5: Adjudicated Thrombotic Vascular Events (Fatal and Non-Fatal) in the ASCENDD Trial<sup>a</sup>
                           </caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Event</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JESDUVROQ</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,482)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">rhEPO</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,474)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Rate per 100 PY</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Rate per 100 PY</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Vascular access thrombosis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5.0</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Myocardial infarction</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3.4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Stroke</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Deep vein thrombosis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>Pulmonary embolism</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0.3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0.4</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>PY=Person Years; rhEPO=Recombinant human erythropoietin.</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <sup>a</sup>
                           </content> These data are not an adequate basis for comparison of rates between the study drug and the active control.</paragraph>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5a4e3f3f-8cc7-4087-b915-2965885321d5">
               <id root="ee6829f3-8d82-4c3f-90ed-51a26ae8b99f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20230201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Moderate CYP2C8 Inhibitors: Reduce starting dose. (<linkHtml href="#ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">7.1</linkHtml>)</item>
                           <item>
                              <caption></caption>CYP2C8 Inducers: Monitor hemoglobin and adjust the dose of JESDUVROQ as appropriate. (<linkHtml href="#ID_a14f9322-e806-461f-b097-08676aa7c60c">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">
                     <id root="a0ba84c9-f367-4fe8-92ec-f1de8e9d9149"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 CYP2C8 Inhibitors </title>
                     <text>
                        <paragraph>Concomitant administration of strong CYP2C8 inhibitors (e.g., gemfibrozil) with JESDUVROQ is contraindicated due to a marked increase in daprodustat exposure <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_29ab096f-bf1d-4430-874d-6615e461b6fe">4</linkHtml>), Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>. Concomitant administration of moderate CYP2C8 inhibitors (e.g., clopidogrel) increases daprodustat exposure <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>. Reduce the starting dose of JESDUVROQ by half when initiating treatment in patients on clopidogrel or a moderate CYP2C8 inhibitor except in patients whose starting dose is already 1 mg. Monitor hemoglobin and adjust the dose of JESDUVROQ when initiating or stopping therapy with clopidogrel or a moderate CYP2C8 inhibitor during treatment with JESDUVROQ <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_fbe0a52f-bffd-4553-9983-3e9ccdd7db41">2.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a14f9322-e806-461f-b097-08676aa7c60c">
                     <id root="72baf33c-4cfc-4e70-b7b8-927254762ddd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 CYP2C8 Inducers </title>
                     <text>
                        <paragraph>CYP2C8 inducers (e.g., rifampin) may decrease daprodustat exposure, which may result in loss of efficacy. Monitor hemoglobin and adjust the dose of JESDUVROQ when initiating or stopping therapy with CYP2C8 inducers during treatment with JESDUVROQ <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3e2b0e6e-b1d8-4074-bb04-627958db12ec">
               <id root="c6980127-c39e-4d94-a343-c57dcc489e91"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20230830"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption></caption>Pregnancy: May cause fetal harm. (<linkHtml href="#ID_e27b20fb-f7aa-47de-ac2a-339dcf6f9089">8.1</linkHtml>)</item>
                           <item>
                              <caption></caption>Lactation: Breastfeeding not recommended until one week after the final dose. (<linkHtml href="#ID_3ee64053-35d0-45a5-8177-2ae1dfcf0832">8.2</linkHtml>)</item>
                           <item>
                              <caption></caption>Hepatic Impairment: Reduce the starting dose in patients with moderate hepatic impairment (Child-Pugh Class B). JESDUVROQ not recommended in severe hepatic impairment (Child-Pugh Class C). (<linkHtml href="#ID_743fd794-9388-4343-8f8c-a2736186ee2b">8.6</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_e27b20fb-f7aa-47de-ac2a-339dcf6f9089">
                     <id root="b7bbb65e-c2cf-4e4a-983b-adf665027add"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data with JESDUVROQ use in pregnant women are insufficient to establish a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and the fetus associated with CKD (<content styleCode="italics">see <linkHtml href="#_RefClinicalConsiderations1">Clinical Considerations</linkHtml>
                           </content>)<content styleCode="italics">. </content>Daprodustat administered orally to pregnant rats and rabbits during the period of organogenesis was associated with adverse fetal outcomes, including embryonic and fetal loss and reduced fetal weight, at doses that caused maternal toxicity and polycythemia (<content styleCode="italics">see <linkHtml href="#_Refdata1">Data</linkHtml>). </content>Advise pregnant women of the potential risk to the fetus.</paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <paragraph ID="_RefClinicalConsiderations1">
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Disease-Associated Maternal and/or Embryo/Fetal Risk: CKD in pregnancy increases the risk for maternal hypertension, preeclampsia, miscarriage, stillbirth, preterm delivery, low birth weight infants, and polyhydramnios.</paragraph>
                        <paragraph ID="_Refdata1">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>: Daprodustat was orally administered to pregnant rats at 0.5, 7, or 60 mg/kg/day from gestation day 6 to gestation day 17 during the period of organogenesis. No adverse effects were observed at doses less than or equal to 7 mg/kg/day (3 times the maximum recommended human dose [MRHD] based on body surface area). Daprodustat administration resulted in post-implantation loss, increased embryofetal death, and reduction in skeletal ossification in rats at a dose of 60 mg/kg/day (24 times the MRHD based on body surface area), which was associated with maternal toxicity (reduced body weight gain or weight loss). Maternal toxicity occurred at doses associated with polycythemia.</paragraph>
                        <paragraph>Daprodustat was orally administered to pregnant rabbits at doses of 4, 30, or 60 mg/kg/day from gestation day 7 until gestation day 19 during the period of organogenesis. No adverse effects were observed at doses less than or equal to 30 mg/kg/day (24 times the MRHD based on body surface area). Daprodustat administration was associated with a low incidence of abortions and fetal skeletal malformations (irregularly shaped anterior fontanelle, manubrium, fused sternal centra, and microphthalmia) at a dose of 60 mg/kg/day (49 times the MRHD based on body surface area) in the presence of maternal toxicity (reduced body weight gain or weight loss) and polycythemia.</paragraph>
                        <paragraph>In a pre- and postnatal development study, pregnant rats were dosed orally with daprodustat from implantation until weaning (gestation day 6 to lactation day 21) at 0.8, 7, or 40 mg/kg/day concomitantly with 3 major human metabolites of daprodustat. No adverse effects were observed at doses less than or equal to 7 mg/kg/day (3 times the MRHD based on body surface area). Maternal toxicity (in the presence of polycythemia) was noted at 40 mg/kg/day (16 times the MRHD based on body surface area), which was associated with increased pup deaths and decreased pup weights.</paragraph>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3ee64053-35d0-45a5-8177-2ae1dfcf0832">
                     <id root="864c2324-340f-4d0c-affb-230d3d1f4c14"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data on the presence of daprodustat in human milk, the effects on the breastfed child, or the effects on milk production. Daprodustat is present in the milk of lactating rats <content styleCode="italics">(see Data)</content>. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Given the serious adverse reactions seen in adults treated with JESDUVROQ, such as thrombotic vascular events, advise patients not to breastfeed during treatment with JESDUVROQ, and for one week after the final dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>In a pre- and postnatal development study in rats, when daprodustat was orally administered to maternal rats during the lactation period, the drug was detected in plasma of suckling pups on postnatal day 10. The plasma concentration of daprodustat in pups was 2.3% to 3.7% of daprodustat detected in the plasma of dams when dosed at 40 mg/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2ca3f4a8-24a3-4eac-8682-81f9940b5b66">
                     <id root="db7d3989-4c15-4a50-9839-a510204aa072"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>Safety and effectiveness of JESDUVROQ in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8054ecc7-bc1e-44b1-9aa5-4b03eb032d79">
                     <id root="66c98c0c-7714-47b1-85cf-23c3dc02aeb5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the total number of subjects treated with JESDUVROQ in the ASCEND-D study (n=2,964), 480 (32%) subjects were aged 65 years and older, and 159 (11%) were aged 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. No other reported clinical experience has identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_743fd794-9388-4343-8f8c-a2736186ee2b">
                     <id root="cb39a016-2a05-4f4d-9194-500ebc716561"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>No adjustment of the starting dose is required in patients with mild hepatic impairment (Child-Pugh Class A).</paragraph>
                        <paragraph>Reduce the starting dose of JESDUVROQ by half in patients with moderate hepatic impairment (Child-Pugh Class B) except in patients whose starting dose is already 1 mg <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#ID_365b6de7-f450-4349-9b83-60378f8b88c4">12.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>JESDUVROQ has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Therefore, JESDUVROQ is not recommended in patients with severe hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_361e243e-7ff6-4e36-945c-ccec8b8848a2">
               <id root="06443068-6dd5-42cf-817c-88da1d13d9bd"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE </title>
               <effectiveTime value="20230201"/>
               <component>
                  <section ID="ID_ad031d10-3f25-46a6-a647-fd861381ea13">
                     <id root="3cca02ef-8aab-4cf9-9909-2c74025626d3"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance </title>
                     <text>
                        <paragraph>JESDUVROQ contains daprodustat, which is not a controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_bf5bc12c-3851-498e-8041-965ce9faa681">
                     <id root="4094a488-4101-4911-8904-51bc0f28f373"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse </title>
                     <text>
                        <paragraph>Drug abuse is intentional non-therapeuticuse of a drug, even once, for its rewarding psychological or physiological effects. Abuse of JESDUVROQ may be seen in athletes for the effects on erythropoiesis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Abuse-Related Adverse Reactions</content>
                        </paragraph>
                        <paragraph>There are no data on the abuse of JESDUVROQ in humans. Daprodustat and its metabolites neither selectively penetrate the central nervous system, nor produce behavioral effects in animals that are consistent with central nervous system activity.</paragraph>
                        <paragraph>Misuse of drugs that increase erythropoiesis, such as JESDUVROQ, by healthy persons may lead to polycythemia, which may be associated with life-threatening cardiovascular complications (e.g., stroke, myocardial infarction, and thromboembolism).</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4bf32b44-f8e9-4b4d-bf3f-5ad3b1a3cb17">
               <id root="11b653bb-9029-46fd-8550-7236a1d816f8"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Headache and gastrointestinal adverse reactions (e.g., nausea) may be seen with acute overdose with JESDUVROQ. There is no specific antidote. Hemodialysis will not substantially remove daprodustat because it is highly protein bound.</paragraph>
               </text>
               <effectiveTime value="20230201"/>
            </section>
         </component>
         <component>
            <section ID="ID_1e36ba74-5181-40c1-8ece-03ca742fb840">
               <id root="a6a6cd63-610a-42ef-a33b-c603817cb603"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>JESDUVROQ contains daprodustat, an inhibitor of hypoxia inducible factor (HIF), prolyl 4-hydroxylases (PH)1, PH2 and PH3. The chemical name of daprodustat is N[(1,3dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl) carbonyl]glycine. The molecular formula of daprodustat is C<sub>19</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>, and its molecular mass is 393.43. The structural formula is shown below.</paragraph>
                  <renderMultiMedia ID="id690724088" referencedObject="AB2BFB16-4960-4D0C-88A5-8D89F940787E"/>
                  <paragraph>Daprodustat is a white to off-white powder that is poorly soluble in water.</paragraph>
                  <paragraph>Each JESDUVROQ oral tablet contains 1 mg, 2 mg, 4 mg, 6 mg, or 8 mg of daprodustat. Inactive ingredients include colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, mannitol and microcrystalline cellulose. The tablet film-coating inactive ingredients include hypromellose, iron oxide black (1 mg, 2 mg, and 6 mg tablets), iron oxide red and iron oxide yellow (1 mg, 2 mg, 6 mg, and 8 mg tablets), polyethylene glycol, and titanium dioxide.</paragraph>
               </text>
               <effectiveTime value="20230201"/>
               <component>
                  <observationMedia ID="AB2BFB16-4960-4D0C-88A5-8D89F940787E">
                     <text>N [(1,3 dicyclohexylhexahydro-2,4,6-trioxopyrimidin-5-yl) carbonyl]glycine chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jesduvroq-spl-graphic-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_14521a24-f27f-46b3-a1bd-ec630df70b8e">
               <id root="0f1c6dc8-a9b8-494d-a0f6-4f97cf32314c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20230201"/>
               <component>
                  <section ID="ID_15c96c2c-cc60-488c-8f17-9b1be3f7d362">
                     <id root="2fd3329e-7209-474b-be5c-d38513bdc207"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Daprodustat is a reversible inhibitor of HIF-PH1, PH2 and PH3 (IC<sub>50</sub> in the low nM range). This activity results in the stabilization and nuclear accumulation of HIF-1 and HIF-2 transcription factors, leading to increased transcription of the HIF-responsive genes, including erythropoietin.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3247e56-c343-4df1-9a2a-09eaade64a3a">
                     <id root="9c79f01c-da88-465b-86e2-733a3e24b937"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Effects on Erythropoiesis</content>
                        </paragraph>
                        <paragraph>Daprodustat increases endogenous erythropoietin in a dose-dependent manner within 6 to 8hours after administration. With repeat doses, peak increases in reticulocyte counts occur between 7 and 15 days, with subsequent increases in red blood cell production. New hemoglobin steady-state levels are reached several weeks (approximately 4 weeks in ESA-users and approximately 16-20 weeks in ESA-non-users) after initial administration.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Effects on Iron Metabolism and Utilization</content>
                        </paragraph>
                        <paragraph>Daprodustat increased serum transferrin and total iron binding capacity (TIBC) and decreased serum ferritin, transferrin saturation, and hepcidin when administered for 52 weeks in adults on dialysis with anemia due to CKD.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a dose 10 times the maximum recommended dose, daprodustat does not prolong the QTc interval to any clinically relevant extent.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_365b6de7-f450-4349-9b83-60378f8b88c4">
                     <id root="98d1229f-4c10-4040-aae7-d525c064100b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Daprodustat exposure generally increases in a dose-proportional manner over the range of approved doses. Steady-state concentrations are achieved within 24-hours of dosing.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Following oral administration, daprodustat is readily absorbed with median time to peak concentration (T<sub>max</sub>) in healthy subjects ranging from 1 hour to 4 hours. The absolute bioavailability of daprodustat is 65%. Administration of JESDUVROQ with a high fat/high calorie meal did not significantly alter daprodustat exposure compared to administration in the fasted state.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Daprodustat has an approximately equal distribution between plasma and blood cells (blood:plasma ratio of 1.23). Following intravenous dosing, the volume of distribution at steady-state in healthy subjects is 14.3 L. In vitro, plasma protein binding of daprodustat is &gt;99%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The terminal elimination half-life of daprodustat is approximately 1 hour to 4 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism:</content> In vitro, daprodustat is primarily metabolized by CYP2C8 (95% contribution), with a minor contribution by CYP3A4 (5%).</paragraph>
                        <paragraph>Following oral or intravenous administration of radiolabeled daprodustat to healthy adults, approximately 40% of the total circulating radioactivity in plasma was daprodustat, and the remaining 60% was metabolites.</paragraph>
                        <paragraph>In patients treated with JESDUVROQ, the parent drug is the principal circulating component in plasma. Three metabolites, each accounting for more than 10% of circulating drug-related material, have been identified; in vitro and non-clinical data suggest that each may contribute to the pharmacologic response in vivo; however, the extent of this contribution is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion:</content> Mean clearance from plasma was 18.9 L/h, which correlates to blood clearance of 15L/h and equates to a hepatic extraction of approximately 18%.</paragraph>
                        <paragraph>Within seven days of an oral dose of radiolabeled daprodustat, 74% of the radioactivity was recovered in the feces, and 21% in the urine. Approximately 99.5% of the dose was excreted as oxidative metabolites, with the rest accounted for by daprodustat.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Elderly: </content>Population pharmacokinetic analyses in adults with CKD (22 years to 93 years) showed that age did not influence the pharmacokinetics of daprodustat.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment: </content>The steady-state exposure of daprodustat is similar in patients with normal renal function and those with varying degrees of renal impairment; daprodustat exposure is not significantly impacted by hemodialysis or peritoneal dialysis. The systemic exposure of daprodustat metabolites was higher in patients with Stage 3 to 5 CKD compared to those with normal renal function. Exposures of metabolites were higher on non-dialysis days compared to dialysis days.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment:</content> Following administration of a single JESDUVROQ 6 mg dose, mean daprodustat C<sub>max</sub> and AUC increased by 2-fold and unbound exposure increased by 2.3-fold in subjects with moderate hepatic impairment (ChildPugh Class B) compared to subjects with normal hepatic and renal function. For those with mild hepatic impairment (ChildPugh Class A), mean daprodustat C<sub>max</sub> was similar while AUC increased by 1.5-fold and unbound C<sub>max</sub> and AUC increased by 1.6 and 2.2-fold, respectively, compared to subjects with normal hepatic and renal function. The effect of severe hepatic impairment (ChildPugh Class C) on the pharmacokinetics of daprodustat is unknown as there have been no studies of JESDUVROQ in patients with severe hepatic impairment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies: Effect of CYP2C8 Inhibitors on the Pharmacokinetics of Daprodustat: </content>The concomitant administration of gemfibrozil 600 mg twice a day for 5 days (strong CYP2C8 inhibitor) with a single 100 mg dose of JESDUVROQ on Day 4 of gemfibrozil administration resulted in an 18.6fold increase in AUC<sub>(0-)</sub> and a 3.9-fold increase in C<sub>max</sub> of daprodustat <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_29ab096f-bf1d-4430-874d-6615e461b6fe">4</linkHtml>)]</content>.</paragraph>
                        <paragraph>The concomitant administration of trimethoprim 200 mg twice a day for 5 days (CYP2C8 weak inhibitor) and 25 mg single dose of JESDUVROQ on Day 4 of trimethoprim administration resulted in a 1.5-fold increase in AUC<sub>(0-)</sub> and a 1.3fold increase in C<sub>max</sub> of daprodustat.</paragraph>
                        <paragraph>Daprodustat AUC and C<sub>max</sub> are expected to increase at least 4-fold and 3-fold, respectively, following concomitant administration of daprodustat with clopidogrel 75 mg once daily (moderate CYP2C8 inhibitor).</paragraph>
                        <paragraph>Following 4 weeks of JESDUVROQ dosing, hemoglobin changes from baseline were similar in subjects with and without concomitant use of clopidogrel.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Daprodustat on the Pharmacokinetics of Other Drugs:</content> Clinical drug interaction studies showed that daprodustat inhibition of CYP2C8 and OATP1B1/OATP1B3 demonstrated no clinically significant effect on pioglitazone (CYP2C8 substrate) or rosuvastatin (OATP1B1/OATP1B3 substrate) C<sub>max</sub> or AUC.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro studies:</content> Some oxidative metabolites of daprodustat are substrates of Organic Anion Transporter (OAT)1 or OAT3; however, the clinical significance of this is unknown. Daprodustat is a substrate of Breast Cancer Resistance Protein (BCRP); however, the risk of significant drug interactions between daprodustat and BCRP inhibitors is considered low given the absorption and metabolism profile of daprodustat.</paragraph>
                        <paragraph>Daprodustat is not an inducer of CYP1A2, CYP2B6 and CYP3A4. Daprodustat is not an inhibitor of P-glycoprotein (P-gp) and BCRP.</paragraph>
                        <paragraph>Daprodustat is not a substrate of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and P-gp. The major metabolites are not substrates of OATP1B1, OATP1B3, OATP2B1, Organic Cation Transporter (OCT)1, OCT2, Multidrug and Toxin Extrusion (MATE)1 and MATE2-K. Daprodustat and its major metabolites are not inhibitors of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, OATP1B1, OATP1B3, OATP2B1, OCT1, OAT1, OAT3, OCT2, MATE1 and MATE2-K.</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f827c6bd-fd42-47ca-a7b8-292ae6a21c4f">
               <id root="0247ca01-1b0d-4115-b043-e023c252b0a8"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20230201"/>
               <component>
                  <section ID="ID_4634c38a-14c2-483b-b9ba-698c2e76e517">
                     <id root="3015385e-2c7b-493e-a804-cec0ba95acbe"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Daprodustat was not carcinogenic in two-year carcinogenicity studies when administered orally at doses of 0.02, 0.1, 0.8, or 4 mg/kg/day (males) / 7 mg/kg/day (females) in rats (up to 3 times the MRHD based on body surface area) and 0.2, 0.8, or 3 mg/kg/day (including subcutaneous injection of major human metabolites of daprodustat) in mice (approximating the MRHD based on body surface area).</paragraph>
                        <paragraph>Daprodustat was negative for mutagenic or clastogenic potential in the in vitro bacterial reverse mutation assay, the in vitro human lymphocyte chromosomal aberration assay, and the in vivo rat bone marrow micronucleus assay.</paragraph>
                        <paragraph>In a fertility and early embryonic development study in rats, daprodustat was administered orally at doses of 2, 7, or 100 mg/kg/day in females, resulting in maternal toxicity of reduced body weight gain and decreased mean uterine weight (in the presence of polycythemia), associated with decreased number of corpora lutea, implantations, and live fetuses, and increased post-implantation loss at the dose of 100 mg/kg/day (41 times the MRHD based on body surface area).</paragraph>
                     </text>
                     <effectiveTime value="20230201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5a7b4873-1627-49de-9905-d74e709c318f">
               <id root="0580a5e1-891d-4a3f-bf50-82da2ebc8fb6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <effectiveTime value="20230830"/>
               <component>
                  <section ID="ID_192725f0-0ca3-4c67-904c-645840982fc6">
                     <id root="131f6078-690d-46e0-8091-01c443390ed0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Anemia Due to Chronic Kidney Disease in Adults on Dialysis </title>
                     <text>
                        <paragraph>The efficacy and safety of JESDUVROQ were evaluated in 2,964 adults with anemia due to CKD on dialysis and receiving an ESA at the time of study entry in a randomized, sponsor-blind, active-controlled, global, multicenter, event-driven clinical trial (ASCEND-D; NCT02879305). Patients were stratified by dialysis type and were required to be on dialysis for at least 4 months prior to the first dose of JESDUVROQ. Patients on hemodialysis (HD) were randomized 1:1 to receive oral JESDUVROQ (n=1,316) or intravenous epoetin alfa (n=1,308) while patients on peritoneal dialysis (PD) were randomized 1:1 to receive oral JESDUVROQ (n=171) or subcutaneous darbepoetin alfa (n=169).</paragraph>
                        <paragraph>Key exclusion criteria included: ferritin 100ng/ml (100mcg/L), transferrin saturation 20% at screening; evidence of non-renal anemia; cardiovascular abnormalities (including myocardial infarction, acute coronary syndrome, stroke or transient ischemic attack within 4 weeks of screening, New York Heart Association (NYHA) Class IV heart failure, and uncontrolled hypertension); liver disease; history of malignancy within 2 years of screening; current treatment of cancer and complex kidney cyst.</paragraph>
                        <paragraph>Dosing in each treatment arm followed a protocol-specified adjustment algorithm to achieve and/or maintain a hemoglobin target of 10to11g/dL. The starting dose of JESDUVROQ was 4mg, 6 mg, 8 mg, or 12 mg orally once daily, based on prior ESA dose. The starting dose of either epoetin alfa (HD patients) or darbepoetin alfa (PD patients) was the same as the patients current dose rounded to the nearest study dose. Patients receiving other ESAs were switched to the epoetin alfa or darbepoetin alfa equivalent starting dose. The median doses at Week 52 were 6 mg per day for JESDUVROQ, 8,000 units per week for epoetin alfa, and 150 mcg every four weeks for darbepoetin alfa. Most patients (86%) were exposed to randomized treatment for greater than 6 months (median 26 months for JESDUVROQ and 26 months for rhEPO). The median number of dose adjustments from Day 1 to Week 28 was 2 (interquartile range: 1 to 3) for JESDUVROQ and 2 (interquartile range: 1 to 3) for rhEPO. The median number of dose adjustments from Week 28 to Week 52 was 1 (interquartile range: 1 to 2) for JESDUVROQ and 2 (interquartile range: 1 to 3) for rhEPO.</paragraph>
                        <paragraph>The mean age of the patients in this study was 57 years (range 18-95), 57% were males, 67% were Caucasian, 16% were Black, and 12% were Asian. In the US region, 39% of patients were Black. Approximately 25% of the population was Hispanic or Latino. The largest regions of enrollment were the US (29%) and Eastern Europe/South Africa (28%). Common comorbid conditions included hypertension (92%), hyperlipidemia (50%) and diabetes mellitus (42%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Effects on Hemoglobin</content>
                        </paragraph>
                        <paragraph>The efficacy and safety of JESDUVROQ were evaluated as co-primary endpoints: the mean change in hemoglobin from baseline to the Evaluation Period (Weeks28 to 52) and time to first adjudicated MACE (defined as all-cause mortality, non-fatal myocardial infarction, or non-fatal stroke), using a non-inferiority comparison to rhEPO (epoetin alfa and darbepoetin alfa) for both endpoints.</paragraph>
                        <paragraph>The lower limit of the 95% confidence interval (CI) for the overall hemoglobin treatment difference was greater than the pre-specified non-inferiority margin of -0.75g/dL, demonstrating non-inferiority of JESDUVROQ to rhEPO with respect to the mean change in hemoglobin between baseline and over the Evaluation Period (see <linkHtml href="#_RefTable6">Table 6</linkHtml>). Results were similar in patients receiving either hemodialysis or peritoneal dialysis.</paragraph>
                        <table ID="_RefTable6" width="100%">
                           <caption>Table 6: Change in Hemoglobin in Adults with Anemia Due to Chronic Kidney Disease Receiving Dialysis: ASCEND-D Trial (ITT Analysis)<sup>a</sup>
                           </caption>
                           <col width="49%"/>
                           <col width="26%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Assessment</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JESDUVROQ</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,487)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">rhEPO<sup>b</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,477)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Primary endpoint: change in Hgb<sup>c</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Mean baseline Hgb, g/dL (SD)</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10.4 (1.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10.4 (1.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Hgb change, g/dL (SE)<sup>d,e</sup>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.3 (0.02)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.1 (0.02)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Mean treatment difference (95% CI)<sup>e</sup>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.2 (0.1, 0.2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Change in Hgb - hemodialysis patients<sup>f</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Number of patients</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,316</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,308</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Mean baseline Hgb, g/dL (SD)</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10.4 (1.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10.4 (1.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Hgb change, g/dL (SE)<sup>d,e</sup>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.3 (0.02)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.1 (0.02)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Mean treatment difference (95% CI)<sup>e</sup>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.2 (0.1, 0.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Change in Hgb - peritoneal dialysis patients<sup>f</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Number of patients</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>171</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>169</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Mean baseline Hgb, g/dL (SD)</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10.3 (1.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10.2 (1.0)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Hgb change, g/dL (SE)<sup>d,e</sup>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.4 (0.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.2 (0.1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Mean treatment difference (95% CI)<sup>e</sup>
                                       </item>
                                    </list>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>0.2 (-0.04, 0.3)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CI=Confidence interval; Hgb=Hemoglobin; ITT=Intent to treat; rhEPO=Recombinant human erythropoietin; SD=Standard deviation; SE=Standard error.</paragraph>
                        <paragraph>
                           <sup>a</sup> Intent to Treat (ITT) analyses included observed and imputed values on and off treatment after randomization. Eight percent of patients had no observed hemoglobin during Weeks 28 to 52.</paragraph>
                        <paragraph>
                           <sup>b</sup> Hemodialysis patients received epoetin alfa and peritoneal dialysis patients received darbepoetin alfa.</paragraph>
                        <paragraph>
                           <sup>c</sup> Adjusted for multiplicity.</paragraph>
                        <paragraph>
                           <sup>d</sup> Mean Hgb change from baseline to Evaluation Period (EP): Weeks 28 to 52.</paragraph>
                        <paragraph>
                           <sup>e</sup> Adjusted for baseline covariates.</paragraph>
                        <paragraph>
                           <sup>f</sup> Not adjusted for multiplicity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiovascular Outcomes</content>
                        </paragraph>
                        <paragraph>The hazard ratio for the time to first occurrence of MACE, a composite of all-cause mortality, nonfatal myocardial infarction, and non-fatal stroke, comparing JESDUVROQ to rhEPO was 0.93 (95% CI 0.81, 1.07) (<linkHtml href="#_RefTable7">Table 7</linkHtml>). Non-inferiority of JESDUVROQ to rhEPO on MACE was achieved because the upper limit of the 95% CI for the MACE hazard ratio was less than the prespecified non-inferiority margin of 1.25.</paragraph>
                        <table ID="_RefTable7" width="100%">
                           <caption>Table 7: Major Adverse Cardiovascular Events in the ASCEND-D Trial (ITT Analysis)<sup>a</sup>
                           </caption>
                           <col width="50%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Co-primary composite endpoint</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">JESDUVROQ</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,487)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">rhEPO<sup>b</sup>
                                       </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(n=1,477)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>First occurrence of MACE<sup>c</sup>, n</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>374</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>394</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Allcause mortality<sup>d</sup>, n</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>244</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>233</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Non-fatal myocardial infarction<sup>d</sup>, n</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>101</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>126</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <list listType="unordered">
                                       <item>
                                          <caption></caption>Non-fatal stroke<sup>d</sup>, n</item>
                                    </list>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>29</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>35</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>Hazard ratio (95% CI)<sup>e</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.93 (0.81, 1.07)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>Incidence rate per 100 PY</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>11.1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>11.9</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CI=Confidence interval; ITT=Intent to treat; MACE=Major adverse cardiovascular events; PY=Person Years; rhEPO=Recombinant human erythropoietin.</paragraph>
                        <paragraph>
                           <sup>a</sup> ITT analyses included events on and off treatment after randomization.</paragraph>
                        <paragraph>
                           <sup>b</sup> Hemodialysis patients received epoetin alfa; peritoneal dialysis patients received darbepoetin alfa.</paragraph>
                        <paragraph>
                           <sup>c</sup> Co-primary endpoint.</paragraph>
                        <paragraph>
                           <sup>d</sup> Component of composite endpoint.</paragraph>
                        <paragraph>
                           <sup>e</sup> Adjusted for baseline covariates.</paragraph>
                     </text>
                     <effectiveTime value="20230830"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f265a939-2b1c-4c38-85e3-4dc8724650fa">
               <id root="53a6a672-ea6f-41c9-b8d7-a97b0ec207ee"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>JESDUVROQ tablets contain 1 mg, 2 mg, 4 mg, 6 mg or 8 mg of daprodustat.</paragraph>
                  <table width="100%">
                     <col width="18%"/>
                     <col width="46%"/>
                     <col width="36%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Tablet</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Strength</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Package Configuration</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">and NDC Number</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Tablet Description</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">and Markings</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>1 mg</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>30 count bottle</paragraph>
                              <paragraph>(NDC 0173-0897-13)</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Round, gray, biconvex, film-coated tablets debossed with GS KF on one side</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>100 count blister pack</paragraph>
                              <paragraph>(NDC 0173-0897-56)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>2 mg</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>30 count bottle</paragraph>
                              <paragraph>(NDC 0173-0903-13)</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Round, yellow, biconvex, film-coated tablets debossed with GS V7 on one side</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>100 count blister pack</paragraph>
                              <paragraph>(NDC 0173-0903-56)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>4 mg</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>30 count bottle</paragraph>
                              <paragraph>(NDC 0173-0906-13)</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Round, white, biconvex, film-coated tablets debossed with GS 13 on one side</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>100 count blister pack</paragraph>
                              <paragraph>(NDC 0173-0906-56)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>6 mg</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>30 count bottle</paragraph>
                              <paragraph>(NDC 0173-0911-13)</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Round, pink, biconvex, film-coated tablets debossed with GS IM on one side</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>100 count blister pack</paragraph>
                              <paragraph>(NDC 0173-0911-56)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>8 mg</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>30 count bottle</paragraph>
                              <paragraph>(NDC 0173-0914-13)</paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Round, orange, biconvex, film-coated tablets debossed with GS 5E on one side</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>100 count blister pack</paragraph>
                              <paragraph>(NDC 0173-0914-56)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F to 86F). [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20230830"/>
            </section>
         </component>
         <component>
            <section ID="ID_73f80dd0-b95f-4798-8bf7-4d12553cca04">
               <id root="201b1e74-e2c5-4d07-96aa-ae4ccde0c5a3"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>
                     <content styleCode="italics">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</content>
                  </paragraph>
                  <paragraph>Inform patients:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption></caption>Of the increased risks of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_e2fe8e0d-acd3-479d-b861-2375f3ab9a92">5.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Of the risk of hospitalization due to heart failure, the symptoms and signs of heart failure and to promptly report these symptoms to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7199c810-353e-44c5-9b7a-ae466d13183f">5.2</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Of the risk of hypertension, to undergo regular blood pressure monitoring and to adhere to the prescribed anti-hypertensive regimen <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_dc714e86-7a41-4251-9423-7424fdeff516">5.3</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Of the risk of gastric erosions and gastrointestinal bleeding, the associated symptoms and signs and to report these symptoms to their healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_8554eea2-5f45-416c-a3de-fa31306d0ec5">5.4</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Of the need to have regular laboratory tests for hemoglobin<content styleCode="italics"> [see Dosage and Administration (<linkHtml href="#ID_0015a512-c3b9-4d87-bc44-3876cc58d3cc">2.1</linkHtml>, <linkHtml href="#ID_b12fd006-4c44-4ed4-8f30-0193b1896562">2.4</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>Of the need to inform their healthcare provider if they are taking strong CYP2C8 inhibitors, including gemfibrozil or moderate CYP2C8 inhibitors <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_29ab096f-bf1d-4430-874d-6615e461b6fe">4</linkHtml>), Drug Interactions (<linkHtml href="#ID_9a1dbb1a-cff1-4c02-b33d-e91fd9d679ac">7.1</linkHtml>)]</content>.</item>
                     <item>
                        <caption></caption>
                        <content styleCode="underline">Pregnancy</content>
                     </item>
                     <item>
                        <caption></caption>JESDUVROQ may cause fetal harm. Advise females to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_e27b20fb-f7aa-47de-ac2a-339dcf6f9089">8.1</linkHtml>)].</content>
                     </item>
                     <item>
                        <caption></caption>
                        <content styleCode="underline">Lactation</content>
                     </item>
                     <item>
                        <caption></caption>Advise females not to breastfeed during treatment with JESDUVROQ and for one week after the final dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_3ee64053-35d0-45a5-8177-2ae1dfcf0832">8.2</linkHtml>)].</content>
                     </item>
                  </list>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Manufactured by</paragraph>
                  <paragraph>GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>2023 GSK group of companies or its licensor.</paragraph>
                  <paragraph>JDV:3PI</paragraph>
               </text>
               <effectiveTime value="20230830"/>
            </section>
         </component>
         <component>
            <section ID="ID_df62e75b-6bc8-4d3c-9c8a-39bbaa921ef0">
               <id root="1e4ca5e3-0581-43c2-8d6d-733f5b00f09f"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title> </title>
               <text>
                  <paragraph>PHARMACIST - DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</paragraph>
                  <paragraph>- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</paragraph>
                  <table width="100%">
                     <col width="50%"/>
                     <col width="50%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">JESDUVROQ (jezDOOVrok)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(daprodustat)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">tablets</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about JESDUVROQ?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">JESDUVROQ may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Increased risk of death, heart attack, stroke, and blood clots. </content>These risks may happen if you are treated with JESDUVROQ to increase red blood cells (RBCs) to near the same level found in healthy people. These risks may be increased if you have heart or blood vessel problems, or problems with blood flow to your brain (cerebrovascular disease). Blood clots can form in the blood vessels (veins), including in your legs (deep vein thrombosis or DVT), lungs (pulmonary embolism or PE), and in your dialysis access (vascular access thrombosis or VAT).</item>
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Get medical help right away if you get any of the following symptoms:</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption></caption>chest pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>sudden trouble seeing</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>trouble breathing or shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption></caption>sudden trouble walking, dizziness, loss of balance or coordination</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>pain in your leg or arm, with or without swelling</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>lightheadedness or fainting</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>unusual coolness or warmth in arm or leg</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>dialysis access stops working</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption></caption>sudden confusion, trouble speaking, or trouble  understanding others speech</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption></caption>do not feel a vibration (thrill) over the dialysis access area</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="ordered">
                                 <item>
                                    <caption></caption>sudden numbness or weakness in your face, arm, or leg, especially on one side of your body</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">See What are the possible side effects of JESDUVROQ? for more information about side effects.</content>
                              </paragraph>
                              <paragraph>If you decide to take JESDUVROQ, your healthcare provider should prescribe the lowest dose of JESDUVROQ that is necessary to reduce your chance of needing red blood cell transfusions.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is JESDUVROQ?</content>
                              </paragraph>
                              <paragraph>JESDUVROQ is a prescription medicine used to treat anemia that is caused by chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months. People with anemia have a lower-than-normal number of RBCs. JESDUVROQ works by increasing a protein called erythropoietin to help your body make more RBCs. JESDUVROQ is used to reduce or avoid the need for RBC transfusions.</paragraph>
                              <paragraph>If your hemoglobin level stays too high or if your hemoglobin goes up too quickly, this may lead to serious health problems which may result in death. These serious health problems may happen if you take JESDUVROQ, even if you do not have an increase in your hemoglobin levels.</paragraph>
                              <paragraph>JESDUVROQ has not been proven to improve quality of life, tiredness (fatigue), or well-being.</paragraph>
                              <paragraph>JESDUVROQ <content styleCode="bold">should not be used</content>:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>in place of emergency treatment for anemia (red blood cell transfusions).</item>
                                 <item>
                                    <caption></caption>for the treatment of anemia that is caused by CKD in people who are not on dialysis. It is not known if JESDUVROQ is safe and effective in children.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not take JESDUVROQ if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>take certain medicines called strong CYP2C8 inhibitors such as gemfibrozil. Ask your healthcare provider if you are not sure.</item>
                                 <item>
                                    <caption></caption>have high blood pressure that is not controlled (uncontrolled hypertension)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before taking JESDUVROQ, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>have heart disease</item>
                                 <item>
                                    <caption></caption>have had a stroke</item>
                                 <item>
                                    <caption></caption>have a history of heart failure</item>
                                 <item>
                                    <caption></caption>have high blood pressure</item>
                                 <item>
                                    <caption></caption>have a history of damage to the lining of the stomach, the tube that connects the mouth and stomach (esophagus), or intestines</item>
                                 <item>
                                    <caption></caption>have a history of stomach ulcers (peptic ulcer disease)</item>
                                 <item>
                                    <caption></caption>smoke tobacco or drink alcohol</item>
                                 <item>
                                    <caption></caption>have cancer</item>
                                 <item>
                                    <caption></caption>have liver problems</item>
                                 <item>
                                    <caption></caption>are pregnant or plan to become pregnant. JESDUVROQ may cause harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with JESDUVROQ.</item>
                                 <item>
                                    <caption></caption>are breastfeeding or plan to breastfeed. It is not known if JESDUVROQ passes into your breast milk. Do not breastfeed during treatment with JESDUVROQ and for 1 week after your final dose.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take, including</content> prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking JESDUVROQ with certain other medicines may affect the way JESDUVROQ works.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take JESDUVROQ?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Take JESDUVROQ exactly as your healthcare provider tells you to take it.</item>
                                 <item>
                                    <caption></caption>Do not change your dose or stop JESDUVROQ without talking to your healthcare provider.</item>
                                 <item>
                                    <caption></caption>Take your prescribed dose of JESDUVROQ 1 time a day.</item>
                                 <item>
                                    <caption></caption>Swallow JESDUVROQ tablets whole. Do not cut, crush, or chew the tablet.</item>
                                 <item>
                                    <caption></caption>JESDUVROQ can be taken with or without food.</item>
                                 <item>
                                    <caption></caption>JESDUVROQ can be taken at the same time as iron supplements or medicines that control the amount of phosphorus in your blood (phosphate binders), if necessary.</item>
                                 <item>
                                    <caption></caption>If you miss a dose of JESDUVROQ, take it as soon as you remember. If it is the same day as your next dose, skip the missed dose and take your next dose at your usual time. Do not take 2 doses at the same time to make up for the missed dose.</item>
                                 <item>
                                    <caption></caption>If you take more than your prescribed dose of JESDUVROQ, contact your healthcare provider or go to the nearest hospital emergency room right away.</item>
                                 <item>
                                    <caption></caption>Your healthcare provider will do certain blood tests before you start JESDUVROQ and during treatment as needed. Your healthcare provider may change your dose of JESDUVROQ based on the results of your blood tests.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of JESDUVROQ?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">JESDUVROQ may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">See What is the most important information I should know about JESDUVROQ?</content>
                                 </item>
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Risk of hospitalization for heart failure.</content> People who have a history of heart failure have an increased risk of hospitalization for heart failure with JESDUVROQ. Tell your healthcare provider right away if you get worsening signs and symptoms of heart failure, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>shortness of breath or trouble breathing</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>sudden weight gain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>swelling of your feet, ankles or legs</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>feeling tired or weak</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">High blood pressure. </content>High blood pressure is common with JESDUVROQ. Your blood pressure may go up or worsen, and may be difficult to treat during treatment with JESDUVROQ. Your healthcare provider should check your blood pressure regularly during treatment with JESDUVROQ. If your blood pressure increases, your healthcare provider may prescribe a new medicine or may change the dose of your current blood pressure medicine.</item>
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Damage to the lining of the stomach, the tube that connects the mouth and stomach (esophagus), and intestines (gastrointestinal erosion).</content> Your risk of gastrointestinal erosion may increase if you have a history of gastrointestinal erosion, stomach ulcers (peptic ulcer disease), use certain medicines that increase the risk of gastrointestinal erosion, or currently smoke tobacco or drink alcohol. Some people who have bleeding in the stomach and intestines may need to receive transfusions. Tell your healthcare provider if you have any of these symptoms:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>stomach-area (abdominal) discomfort or pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>black, tarry stools</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>nausea or vomiting</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>trouble swallowing</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>blood in your vomit or stool</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>pain in your throat or chest</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>
                                    <content styleCode="bold">Cancer. </content>Cancers have happened in people treated with JESDUVROQ. Talk to your healthcare provider if you have any concerns about cancer.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of JESDUVROQ include:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>high blood pressure. See <content styleCode="bold">High blood pressure</content> above.</item>
                                 <item>
                                    <caption></caption>heart attack, stroke, and blood clots in the dialysis access, legs, or lungs. See <content styleCode="bold">What is the most important information I should know about JESDUVROQ?</content> above.</item>
                                 <item>
                                    <caption></caption>stomach area (abdominal) pain.</item>
                              </list>
                              <paragraph>These are not all the possible side effects of JESDUVROQ.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store JESDUVROQ?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption></caption>Store JESDUVROQ at room temperature between 68F to 77F (20C to 25C).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep JESDUVROQ and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of JESDUVROQ.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use JESDUVROQ for a condition for which it was not prescribed. Do not give JESDUVROQ to other people, even if they have the same symptoms that you have. It may harm them.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information about JESDUVROQ that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in JESDUVROQ?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active Ingredient:</content> daprodustat.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive Ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, mannitol, and microcrystalline cellulose.</paragraph>
                              <paragraph>Tablet film-coating<content styleCode="bold">: </content>hypromellose, iron oxide black (1 mg, 2 mg, and 6 mg tablets), iron oxide red and iron oxide yellow (1 mg, 2 mg, 6 mg, and 8 mg tablets), polyethylene glycol, and titanium dioxide.</paragraph>
                              <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                              <paragraph>Manufactured by</paragraph>
                              <paragraph>GlaxoSmithKline</paragraph>
                              <paragraph>Durham, NC 27701</paragraph>
                              <paragraph>2023 GSK group of companies or its licensor.</paragraph>
                              <paragraph>JDV:1MG </paragraph>
                              <paragraph>For more information, go to <linkHtml href="http://www.JESDUVROQ.com">www.JESDUVROQ.com</linkHtml> or call GlaxoSmithKline (GSK) at 1-888-825-5249.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered">
                     <item>
                        <caption></caption>This Medication Guide has been approved by the U.S. Food and Drug Administration	Issued: February 2023</item>
                  </list>
               </text>
               <effectiveTime value="20230830"/>
            </section>
         </component>
         <component>
            <section ID="ID_f1d2aca5-a530-4069-bc50-4a9520f7b6ee">
               <id root="2844c666-cce8-4011-98dc-292b8792d6ce"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0897-13</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Jesduvroq</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daprodustat) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GSK</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 tablets</content>
                  </paragraph>
                  <paragraph>Each tablet contains 1 mg of daprodustat.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablets whole.  Do not cut, crush or chew the tablet.</content>
                  </paragraph>
                  <paragraph>Store at 20C to 25C (68F to 77F); exclusions permitted between 15C and 30C (59F to 86F). [See USP Controlled Room Temperatures].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not accept if safety seal under cap is broken or missing.</content>
                  </paragraph>
                  <paragraph>Recommended Dosage:</paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Mfd. By: GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>Product of Singapore</paragraph>
                  <paragraph>2023 GSK or licensor.</paragraph>
                  <paragraph>Rev. 3/23</paragraph>
                  <paragraph>A087261 (62000000087261)</paragraph>
                  <renderMultiMedia ID="id-873543720" referencedObject="ID_01594c17-e73a-4d08-a6bd-683fcefb5fd9"/>
               </text>
               <effectiveTime value="20230713"/>
               <component>
                  <observationMedia ID="ID_01594c17-e73a-4d08-a6bd-683fcefb5fd9">
                     <text>Jesduvroq 1 mg tablet 30 count label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jesduvroq-spl-graphic-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e175d16f-c498-45ae-a38d-16be23e6b171">
               <id root="da8cb12a-b316-4f45-a2b9-81976664f6f9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0903-13</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Jesduvroq</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daprodustat) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GSK</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 tablets</content>
                  </paragraph>
                  <paragraph>Each tablet contains 2 mg of daprodustat.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablets whole.  Do not cut, crush or chew the tablet.</content>
                  </paragraph>
                  <paragraph>Store at 20C to 25C (68F to 77F); exclusions permitted between 15C and 30C (59F to 86F). [See USP Controlled Room Temperatures].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not accept if safety seal under cap is broken or missing.</content>
                  </paragraph>
                  <paragraph>Recommended Dosage:</paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Mfd. By: GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>Product of Singapore</paragraph>
                  <paragraph>2023 GSK or licensor.</paragraph>
                  <paragraph>Rev. 3/23</paragraph>
                  <paragraph>A087262 (62000000087262)</paragraph>
                  <renderMultiMedia ID="id-598023063" referencedObject="A6BE315B-F916-41D7-BD94-5364F37F278A"/>
               </text>
               <effectiveTime value="20230713"/>
               <component>
                  <observationMedia ID="A6BE315B-F916-41D7-BD94-5364F37F278A">
                     <text>Jesduvroq 2 mg tablet 30 count label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jesduvroq-spl-graphic-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_08232d14-9691-42fe-b4e1-34f1b5a1c799">
               <id root="b3e2a71c-a656-48f6-97be-bb9014e425be"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0906-13</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Jesduvroq</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daprodustat) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">4 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GSK</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 tablets</content>
                  </paragraph>
                  <paragraph>Each tablet contains 4 mg of daprodustat.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablets whole.  Do not cut, crush or chew the tablet.</content>
                  </paragraph>
                  <paragraph>Store at 20C to 25C (68F to 77F); exclusions permitted between 15C and 30C (59F to 86F). [See USP Controlled Room Temperatures].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not accept if safety seal under cap is broken or missing.</content>
                  </paragraph>
                  <paragraph>Recommended Dosage:</paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Mfd. By: GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>Product of Singapore</paragraph>
                  <paragraph>2023 GSK or licensor.</paragraph>
                  <paragraph>Rev. 3/23</paragraph>
                  <paragraph>A087263 (62000000087263)</paragraph>
                  <renderMultiMedia ID="id778307436" referencedObject="DF1C4A6B-2EC2-4C0A-9846-BBA26D4CF7CA"/>
               </text>
               <effectiveTime value="20230713"/>
               <component>
                  <observationMedia ID="DF1C4A6B-2EC2-4C0A-9846-BBA26D4CF7CA">
                     <text>Jesduvroq 4 mg tablet 30 count label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jesduvroq-spl-graphic-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_720351dd-1db3-4bc4-bebe-1b90130cf324">
               <id root="4f4fc745-206a-4930-9650-a0eb74c35789"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0911-13</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Jesduvroq</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daprodustat) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">6 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GSK</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 tablets</content>
                  </paragraph>
                  <paragraph>Each tablet contains 6 mg of daprodustat.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablets whole.  Do not cut, crush or chew the tablet.</content>
                  </paragraph>
                  <paragraph>Store at 20C to 25C (68F to 77F); exclusions permitted between 15C and 30C (59F to 86F). [See USP Controlled Room Temperatures].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not accept if safety seal under cap is broken or missing.</content>
                  </paragraph>
                  <paragraph>Recommended Dosage:</paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Mfd. By: GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>Product of Singapore</paragraph>
                  <paragraph>2023 GSK or licensor.</paragraph>
                  <paragraph>Rev. 3/23</paragraph>
                  <paragraph>A087264 (62000000087264)</paragraph>
                  <renderMultiMedia ID="id-1596164001" referencedObject="ID_588b3dc7-20f9-4ef2-bc0d-f60f4afacf15"/>
               </text>
               <effectiveTime value="20230713"/>
               <component>
                  <observationMedia ID="ID_588b3dc7-20f9-4ef2-bc0d-f60f4afacf15">
                     <text>Jesduvroq 6 mg tablet 30 count label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jesduvroq-spl-graphic-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_85d25262-1663-43ed-837a-a263af41028f">
               <id root="96435587-1c39-42da-878e-b8442b3fbe5e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0173-0914-13</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Jesduvroq</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(daprodustat) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">8 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">GSK</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dispense the accompanying Medication Guide to each patient</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 tablets</content>
                  </paragraph>
                  <paragraph>Each tablet contains 8 mg of daprodustat.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Swallow tablets whole.  Do not cut, crush or chew the tablet.</content>
                  </paragraph>
                  <paragraph>Store at 20C to 25C (68F to 77F); exclusions permitted between 15C and 30C (59F to 86F). [See USP Controlled Room Temperatures].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not accept if safety seal under cap is broken or missing.</content>
                  </paragraph>
                  <paragraph>Recommended Dosage:</paragraph>
                  <paragraph>See Prescribing Information.</paragraph>
                  <paragraph>Trademarks are owned by or licensed to the GSK group of companies.</paragraph>
                  <paragraph>Mfd. By: GlaxoSmithKline</paragraph>
                  <paragraph>Durham, NC 27701</paragraph>
                  <paragraph>Product of Singapore</paragraph>
                  <paragraph>2023 GSK or licensor.</paragraph>
                  <paragraph>Rev. 3/23</paragraph>
                  <paragraph>A087265 (62000000087265)</paragraph>
                  <renderMultiMedia ID="id-86782700" referencedObject="EDB0266D-8B1D-4A96-862F-02466CEEACD0"/>
               </text>
               <effectiveTime value="20230713"/>
               <component>
                  <observationMedia ID="EDB0266D-8B1D-4A96-862F-02466CEEACD0">
                     <text>Jesduvroq 8 mg tablet 30 count label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="jesduvroq-spl-graphic-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>